NCT04578600 2025-04-24CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell LymphomaUniversity of California, DavisPhase 1 Completed8 enrolled
NCT03010358 2023-08-08Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin LymphomaOHSU Knight Cancer InstitutePhase 1/2 Completed24 enrolled 16 charts